Having recently been able to present positive data for their lead technology IMCgp100 in uveal melanoma at the American Society of Clinical Oncology (ASCO), Immunocore looks at its future as a homegrown British biotech with confidence. Its CEO Andrew Hotchkiss also shares some of the up-coming investigation programmes for Immunocore’s technology, notably in HIV, HBV and tuberculosis.
Andrew, after 31 years with Eli Lilly, you joined Immunocore last year. Why was this the right move for you at that point in your career?
"Historically, many British biotechnology companies have been acquired or sold their product(s) early in their existence. Immunocore will launch its first product in the ultra-rare disease space on its own"
